New Evidence for True Immunopharmacologic Blockade in Myasthenia Gravis

  • A. K. Lefvert
  • S. Cuenoud
  • B. W. Fulpius
Part of the Advances in Behavioral Biology book series (ABBI, volume 25)


Anti-acetylcholine receptor (anti-AChR) antibodies are generally considered to give rise to the neuromuscular deficiency observed in myasthenia gravis (MG). Their precise mechanism of action is still under discussion (for review, see 12).


Human Skeletal Muscle Ligand Binding Site Motor Endplate Toxin Binding Myasthenic Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Almon, R.R. and Appel, S.H. (1975): Biochim. Biophys. Acta 393:66–77.CrossRefGoogle Scholar
  2. 2.
    Bender, A.N., Engel, W.K., Ringel, S.P., Daniels, M.P. and Vogel, Z. (1975): Lancet 1.:607–609CrossRefGoogle Scholar
  3. 3.
    Bergstrom, K., Franksson, C., Matell, G., Nilsson, B.Y., Persson, A., von Reis, G. and Stensman, R. (1975): Eur. Neurol. 13:19–30.CrossRefGoogle Scholar
  4. 4.
    Bevan, S., Kullberg, R.W. and Heinemann, S.F. (1977): Nature 267:263–265.CrossRefGoogle Scholar
  5. 5.
    Dwyer, D.S., Bradley, R.J., Oh, S.J. and Kemp, G.E. (1979): Clin. Exp. Immunol. 37:448–451.Google Scholar
  6. 6.
    Engel, A.G. (1979): Prog. Brain Res. 49:423–434.CrossRefGoogle Scholar
  7. 7.
    Fulpius, B.W., Miskin, R. and Reich, E. (1980): Proc. Nat. Acad. Sci.77:4326–4330.CrossRefGoogle Scholar
  8. 8.
    Lefvertj A.K. and Bergstrom, K. (1977): Eur. J. Clin. Invest. 7:115–119.CrossRefGoogle Scholar
  9. 9.
    Lefvert, A.K. and Bergstrom, K. (1978): Scand. J. Immunol. 8: 525–533.CrossRefGoogle Scholar
  10. 10.
    Lefvert, A.K. and Matell, G. (1979): In Plasmapheresis and the Immunobiology of Myasthenia Gravis (ed) P.C. Dau, Houghton Mifflin, Boston.Google Scholar
  11. 11.
    Lindstrom, J. (1977): Clin. Immunol. Immunopathol. 7:36–43.CrossRefGoogle Scholar
  12. 12.
    Lindstrom, J. (1979): Adv. Immunol. 27:1–50.CrossRefGoogle Scholar
  13. 13.
    Mittag, T., Kornfeld, P., Tormay, A. and Woo, C. (1976): New Eng. J. Med. 294:691–694.CrossRefGoogle Scholar
  14. 14.
    Monnier, V.M. and Fulpius, B.W. (1977): Clin. Exp. Immunol. 29:16–20.Google Scholar
  15. 15.
    Morell, A., Skvaril, F. and Barandun, S. (1975): IgG-Subklassen der menschlichen Immunoglobuline. Immunochemische, genetische, biologische und klinische Aspekte, S. Karger, Basel.Google Scholar
  16. 16.
    Pinching, A.J., Peters, D.K. and Newsom-Davis, J. (1976): Lancet 2:13–73.Google Scholar
  17. 17.
    Tsujihata, M., Hazama, R., Ishii, N., Ide, Y., Mori, M. And Takamori, M. (1979): Neurology 29:654–661.CrossRefGoogle Scholar
  18. 18.
    Vincent, A. and Newsom-Davis, J. (1979): In Advances in Cyto-pharmacology, Vol. 3, (eds) B. Ceccarelli and F. Clementi, Raven Press, New York.Google Scholar
  19. 19.
    Zum, A. and Fulpius, B.W. (1979): Prog. Brain Res. 49:435–440.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1981

Authors and Affiliations

  • A. K. Lefvert
    • 1
  • S. Cuenoud
    • 1
  • B. W. Fulpius
    • 1
  1. 1.Department of BiochemistryUniversity of Geneva Sciences IIGeneva 4Switzerland

Personalised recommendations